References
- U.S. National Library of Medicine. http://livertox.nih.gov/Narajo.html [last accessed 1 Feb 2015]
- Freifeld AG, Bow EJ, Sepkowitz KA, et al.; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious Diseases Society of America. Clin Infect Dis 2011;52:56–93
- Imhof A, Schaer DJ, Schanz U, Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006;136:739–742
- Eiden C, Peyrière H, Cociglio M, et al. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database. Ann Pharmacother 2007;41:755–763
- Raftery AT, Lim E, Östör AJK. Hallucinations. In: Raftery AT, Lim E, Östör AJK, eds. Churchill's pocketbook of differential diagnosis. New York: Churchill Livingstone Elsevier; 2014:213–215
- Pasqualotto AC, Xavier MO, Andreolla HF, Linden R. Voriconazole therapeutic drug monitoring: focus on safety. Expert Opin Drug Saf 2010;9:125–137
- Zonios DI, Gea-Banacloche J, Childs R, Bennett JE. Hallucinations during voriconazole therapy. Clin Infect Dis 2008;47:e7–e10
- Zrenner E, Tomaszewski K, Hamlin J, et al. Effects of multiple doses of voriconazole on the vision of healthy volunteers: a double-blind, placebo-controlled study. Ophthalmic Res 2014;52:43–52
- Imataki O, Ohnishi H, Kitanaka A, et al. Visual disturbance comorbid with hallucination caused by voriconazole in the Japanese population. Int J Hematol 2008;88:3–6
- Boyd AE, Modi S, Howard SJ, et al. Adverse reactions to voriconazole. Clin Infect Dis 2004;39:1241–1244
- Choi SH, Lee SY, Hwang JY, et al. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. Pediatr Blood Cancer 2013;60:82–87
- Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012;55:1080–1087